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Abstract
The interaction of the epidermal growth factor (EGF) with its receptor (EGFR) is known to be complex, and the common
over-expression of EGF receptor family members in a multitude of tumors makes it important to decipher this interaction
and the following signaling pathways. We have investigated the affinity and kinetics of
125I-EGF binding to EGFR in four
human tumor cell lines, each using four culturing conditions, in real time by use of LigandTracerH. Highly repeatable and
precise measurements show that the overall apparent affinity of the
125I-EGF – EGFR interaction is greatly dependent on cell
line at normal culturing conditions, ranging from KD<200 pM on SKBR3 cells to KD<8 nM on A431 cells. The
125I-EGF – EGFR
binding curves (irrespective of cell line) have strong signs of multiple simultaneous interactions. Furthermore, for the cell
lines A431 and SKOV3, gefitinib treatment increases the
125I-EGF - EGFR affinity, in particular when the cells are starved. The
125I-EGF - EGFR interaction on cell line U343 is sensitive to starvation while as on SKBR3 it is insensitive to gefitinib and
starvation. The intriguing pattern of the binding characteristics proves that the cellular context is important when
deciphering how EGF interacts with EGFR. From a general perspective, care is advisable when generalizing ligand-receptor
interaction results across multiple cell-lines.
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Introduction
Cells are complex units with a heterogeneous surface. It is
therefore likely that a ligand interacting with a cell binds to more
than one receptor. These receptors may be members of the same
receptor family or even the same receptor in different conforma-
tions. Nevertheless, the common discussion about biomolecular
interactions tends to be simplistic. It is often assumed that most
interactions are so called 1:1 interactions, with one monovalent
ligand binding to one specific target [1].
Signs of heterogeneity have been described for the epidermal
growth factor (EGF) interacting with the EGF receptor (EGFR).
Previous results indicate two receptor populations: one binding
with high affinity (10–100 pM) and one with low affinity (1–
10 nM) [2]. The epidermal growth factor receptor family consists
of four members: EGFR (HER1/ErbB1), HER2, HER3 and
HER4. These receptors are known to dimerize, with themselves
(homodimers) or with other members of the EGF receptor family
(heterodimers). To what extent the dimerization occurs and its
correlation to ligand binding and downstream signaling has been
discussed for many years and is not yet fully understood. A
common opinion is that the dimerization requires conformational
changes triggered by the binding of EGF [3,4,5], although some
claim that there can be dimers on the cell surface even without
bound EGF [6,7]. In addition to numerous experimental
procedures, the mechanism of the EGF-EGFR interaction has
been investigated with advanced kinetic modeling tools as well [8].
Atypical expression or activity of EGFR is present in numerous
kinds of cancer [9]. Therefore, the EGF receptor family has
become an important target for cancer therapy. One example is
gefitinib (also denoted IRESSA
TM or ZD1839), designed for
blocking downstream signaling by tyrosine kinase inhibition on
non-small cell lung cancer [10]. The result is inhibited growth, but
the response varies and the majority of patients show no response
to the treatment [11]. Why some cell lines and patients are
resistant to gefitinib treatment remains unclear, although several
hypotheses are mentioned in the literature. For example,
mutations in the intracellular domain linked to internalization
deficiencies are overrepresented in gefitinib sensitive cell lines,
even though gefitinib binds to the mutated EGFR with the same
affinity [12]. Moasser et. al. [13] discusses the link between HER2
expression and gefitinib sensitivity. Gefitinib binding may affect
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e16536the extracellular part as well, with an apparent increase in EGF
uptake, as observed both in gefitinib sensitive cells and in cells
where growth rate is not affected [14].
The aim of this study was to provide new information on the
intricate interaction pattern of EGF and EGFR by comparing the
kinetics and the affinity of the
125I-EGF-EGFR interaction in four
cancer cell lines. We searched for signs of multiple interactions
occurring simultaneously and compared the affinity. The cells
were exposed to four different treatments and gefitinib sensitivity
and impact of starvation of the cell lines were studied.
Theory
Since the reversible 1:1 interaction model is the general choice
when discussing biological interactions, we will start with the same
assumption. It can be described by
LzR<LR ð1Þ
where free ligand L binds to the receptor R to form the complex
LR. The formation over time can be described with the differential
equation
dL R ½ 
dt
~ka: L ½  : R ½  {kd: LR ½  ð 2Þ
where ka (M
21s
21) is the association rate constant and kd (s
21)i s
the dissociation rate constant describing the formation and
dissociation of the complex. The amount of complex can be
rewritten as [15]
LR ½  ~Rtot: L ½ 
L ½  zKD
:ft ðÞ ð 3Þ
where Rtot is the total amount of receptors (bound and unbound)
and KD is the equilibrium dissociation constant (often denoted





Equation (3) can be utilized when calculating the amount of
receptors bound at a specific concentration of the ligand L. For
example, if using a ligand concentration of 0.16KD,1 6KD or
106KD, the amount of bound receptors at equilibrium will be
10%, 50% or 91% respectively.
At steady-state, f(t)=1. In a biological context, the effect of an
interaction often occur long before equilibrium has been reached
(because time to equilibrium can be many hours or days) and the
time for the effect to remain is often due to the dissociation time
[16]. Therefore, it is important to study how fast the ligand
associate and dissociate to its receptor. In these cases f(t), i.e. how
the interaction proceeds over time, can be described by
ft ðÞ association~ 1{e





Equations (5) and (6) describe how the affinity and the curvature of
a real-time binding trace are related. Equation (6) can be
translated as ‘‘the lower the kd, the slower the dissociation’’,
which combined with (4) means that a slow dissociation also is a
sign of a low KD, i.e. a high affinity. Equation (5) is more difficult
to grasp, as both ka and kd are involved, but in general a higher
affinity will result in less curvature and longer time to equilibrium.
Results and Discussion
Interaction analysis of
125I-EGF – EGFR using four cell
lines
Data from stepwise titration affinity experiments was used to
estimate the equilibrium dissociation constant KD of the
125I-EGF –
EGFR interaction. The signal levels from the end of each
125I-EGF
incubation, representing approximately steady-state, were analyzed
using a non-linear regression model describing a 1:1 interaction.
Calculations of KD were made using data from two titration
measurements for each cell line. A 1:1 interaction model is not
sufficient to describe the system, as
125I-EGF seems to bind to the
cells in a multiple manner (seebelow), but the model was still chosen
to provide results comparable with common saturation curve
analysis in literature.
Figure 1 shows the signal versus concentration graphs for each
cell line, together with the calculated affinity fits. The estimated
affinity varied largely: The
125I-EGF – SKBR3 interaction had the
highest affinity, with a KD value of approximately 0.2 nM.
125I-
EGF binds to SKOV3 and U343 cells with an intermediate
strength, with KD values of approximately 0.9 and 1.4 nM
respectively. A431 cells show the weakest interaction, with a KD of
as much as approximately 8 nM. The difference of a factor 40
between the strongest and the weakest interaction came as a
surprise, as the
125I-EGF – EGFR interaction was expected to be
the same no matter the cell. To our best knowledge, there are no
known mutations on the extracellular part of EGFR in any of the
four cell lines that could affect the affinity.
When evaluating the kinetics of the
125I-EGF – EGFR
interaction the data showed signs of multiple interactions taking
place, observed as binding curvatures different from ordinary 1:1
interactions. This was concluded by fitting the binding curves from
the affinity titration to models describing one monovalent ligand
(
125I-EGF) binding to either one or two independent receptors on
the cell with different kinetic parameters. Representative data from
one A431 and one U343 affinity measurement is depicted in
figure 2. Residuals plot were calculated, describing the differences
between the measured data and the calculated fits. It is clear that
the 1:2 model is superior in fitting the data, which can be observed
in the signal versus time plots (Fig. 2A and B, black curves) as well
as in the residual plots where the differences between fitted and
measured data are greater for the 1:1 model than for the 1:2 model
(Fig. 2C and D). The same observations were made for SKBR3
and SKOV3 (data not shown). This indicates that there are at least
two, maybe more, interactions occurring simultaneously, and it is
in line with the description of a low affinity and a high affinity
population of EGFRs [2]. The small fraction of high affinity
EGFR is likely the reason to why its impact is seldom accounted
for, even though there are studies proposing that the high-affinity
receptors are the primary mediators of the EGFR signaling [17].
Worth pointing out is that the effect of the populations on the
interaction measurement will be different depending on the
concentration used. At low concentration the high affinity
interaction will be dominating. At higher concentration the high
affinity receptor may already be saturated, which means that any
signal increase is due to low affinity interactions. This makes it
essential to study a wide concentration span to ensure an accurate
analysis of any multiple interactions.
EGF-EGFR Interaction Varies with Cellular Context
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the multiple simultaneous interactions is the presence of EGFR
homo- and hetero-dimers. Varying EGFR and HER2 receptor
expression levels could lead to different proportions in the homo/
hetero-dimer population and this could play a significant role for
the interaction pattern and apparent affinity for a particular cell
line. A431 and U343 over-express EGFR (2610
6 receptors/cell
and 5610
5 receptors/cell respectively) [18] and have a lower
HER2 expression [13,19]. SKOV3 and SKBR3 have a large
HER2 population and a lower EGFR expression [13].
The effect of starvation and gefitinib on the
125I-EGF –
EGFR interaction
The uptake and retention of
125I-EGF to the cultured cell lines
A431, U343, SKOV3 and SKBR3 were monitored in real-time
using LigandTracer. The cells were exposed to four different
treatments (control, starvation, gefitinib and gefitinib +starvation)
prior to and during the measurements. Uptake measurement
consisted of a two-step incubation, with pairs of concentrations
chosen to receive a clear increase in signal by the second addition
of
125I-EGF. As the affinity study proved that the nature of the
125I-EGF – EGFR interaction varies greatly between the cell lines,
the concentration pairs for the measurement had to be chosen
differently for the cell lines to obtain comparable results for the
treatment effect analysis.
Normalized interaction data for each treatment of A431 shows
good reproducibility for the method (Fig. 3). To enhance visibility,
noise reduced results for all cells are found in figure 4. The curves
have been normalized to have a 100% binding at the end of
incubation 2 to make comparisons possible. This is not equivalent
to having a saturation of the receptors at that point.
The
125I-EGF – A431 interaction is clearly affected by the
presence of gefitinib, in particular in serum free medium. Gefitinib
treated cells have a smaller difference in signal level between the
first and second concentration (Fig. 4A), thus the first concentra-
tion is closer to saturating the receptor population. This means
that there is a shift in the [L]:KD ratio and consequently gefitinib
treatment increases the affinity of the interaction, possibly as much
as 10 times for the gefitinib +starvation cells. A higher affinity is
also observed in the curvature itself, with a slower dissociation.
U343, which does not respond to gefitinib treatment in growth
rate studies [14], may be insensitive to gefitinib regarding the
125I-
EGF -EGFR interaction as well. There are weak signs of an
Figure 1. Saturation measurements showing great differences in affinity. Saturation measurements and non-linear regression 1:1 fits for the
125I-EGF – EGFR interaction on SKBR3 cells (open diamonds, solid line), SKOV3 cells (filled circles, dashed line), U343 cells (open triangles, solid line)
and A431 cells (filled squares, dashed line). The data indicates that the affinity of the interaction varies between the four cell lines, from 0.2 nM for
SKBR3 to 8 nM for A431.
doi:10.1371/journal.pone.0016536.g001
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somewhat slower dissociation. For the starved cells the dissociation
rate is clearly higher, indicating a lower affinity. The results from
the starvation studies (+/2gefitinib) were noisy and in some cases
the cells detached. Starved U343 cells seem more unstable and
binds
125I-EGF with a lower affinity, which is relevant from a drug
design perspective as there is often limitations in proper nutrition
inside solid tumors [20].
Gefitinib clearly affects the
125I-EGF interaction with SKOV3,
although the effect is not as large as for A431 (Fig. 4C). Starvation
has no obvious impact on normal cells, but increases the effect of
gefitinib. Once again gefitinib exposure results in a higher affinity,
observed as a higher saturation of the receptors and, most of all, a
slower dissociation.
The signal-to-noise ratio for the SKBR3 cells was the lowest of all
cell lines due to the low number of EGFR in SKBR3 (Fig. 4D). This
obstructed the analysis some, but we can conclude that there is no
visible,statisticalproven,effectonthe
125I-EGF– EGFR interaction
when the SKBR3 cells are exposed to either starvation or gefitinib.
This is interesting as SKBR3 is the most sensitive to gefitinib of all
four cell lines when studying growth rate inhibition [13].
All in all, gefitinib can affect the binding of
125I-EGF to EGFR
in some cell lines. Sundberg et. al. [14] have previously shown that
the uptake of
125I-EGF increases in the presence of 1 mM gefitinib
for A431 and U343 cells. These studies were made at 37uC and
one of the suggested explanations was that gefitinib affected the
EGF internalization which in turn altered the uptake ability and
the excretion rate of
125I bound to EGF. The link between
internalization and gefitinib has been made by other groups as well
[21,22]. It is however possible that the amplified uptake signal for
U343 and especially A431 as observed by Sundberg et al. [14] can
be explained solely by an increased affinity, since the
125I-EGF
concentration tested (2 nM) is close to KD which makes the
detected output highly sensitive to any affinity changes. The
measurements in this paper were conducted at room temperature,
and no signs of internalization were detected for the U343 cell line
during a 24 hour timeframe (data not shown) implying that
internalization can be neglected in all our experiments. Thus,
gefitinib binding to the intracellular part of the EGF receptor can
apparently change the extracellular binding properties of EGFR.
If this effect is due to conformational changes of the receptor or
intracellular processes is yet to be determined, although the
increased effect of gefitinib in starved A431 and SKOV3 cells
indicate that the condition of the cell is also important.
The surprisingly large difference in affinity of EGF-EGFR
across different cell lines and treatments gives reason for reflection.
Even though we have only investigated one ligand-receptor
interaction in detail, we cannot exclude that the hosting cell line
influences the interaction results also for other receptors. In our
laboratory, we will continue to investigate various ligand-receptor
interactions across different cell lines to better understand the
importance of cellular context.
Conclusions
By use of data from repeatable, high-precision interaction
measurements, we conclude that at normal conditions, EGF
Figure 2. Fitting binding curves to 1:1 and 1:2 interaction models. (A) 1:1 and (B) 1:2 interaction models (black) fitted to titration data of
125I-
EGF binding to A431(green) and U343 (red) cultured cells. The deviations of the fitted models from the data are described in residual plots for the (C)
1:1 and (D) 1:2 interaction models. The 1:1 interaction model fits the data poorly.
doi:10.1371/journal.pone.0016536.g002
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hosting cell line. It is further evident that the addition of gefitinib
or the lack of serum in the cell-culture medium can alter the EGF-
EGFR interaction properties at least 10-fold, but again depending
on the hosting cell line.
We have clear indications on that the apparent EGF-EGFR
interaction is composed of multiple different interactions and that
the affinity varies greatly between the cell lines, but more work is
required to decipher the underlying nature of the EGF-EGFR
interaction. Thus, the EGF receptor family, its multiple interac-
tions with EGF and the effects of intracellular effects remains an
unsolved puzzle with need for further investigation.
From a general perspective, it may be advisable to limit the
discussion of any ligand-receptor interaction to the context of the
hosting cell-line and care is recommended when generalizing
interaction results across multiple cell-lines.
Materials and Methods
Cell culture
The human squamous carcinoma cell line A431 (CLR 1555,
ATCC, Rocksville, MD, USA), the human glioma cell line
U343MGaCl2:6 (denoted U343), the human ovarian carcinoma
cell line SKOV3 (HTB-77, ATCC, Rocksville, MD, USA) and the
human breast cancer cell line SKBR3 (HTB-30, ATCC,
Rocksville, MD, USA) were used in the experiments. The cells
were seeded on a local area of a cell culture dish (Nunclon
TM, Size
100620, NUNC A/S, Roskilde, Denmark), as described previ-
ously [23]. Ham’s F10 cell culture medium (Biochrom Ag, Berlin,
Germany) supplemented with 10% fetal calf serum (Sigma, St
Louis, MO, USA), L-glutamine (2 mM) and PEST (penicillin
100 IU/ml and streptomycin 100 mg/ml, from Biochrom Ag,
Berlin Germany) was used if not otherwise specified. The cells
were grown at 37uC in incubators with humidified air and 5%
C02.
Radiolabeling
2.5 mg human Epidermal growth factor (EGF, Chemicon
International, USA) was labeled at four occasions with 10–20
MBq
125I (Perkin-Elmer, Wellesley, MA, USA) using the
Chloramine-T protocol [24]. Chloramine-T (Sigma, St Louis,
MO, USA) and sodium metabisulfite (Aldrich, Stockholm,
Sweden) were used for the labeling reactions. Excess reagents
were separated from the protein using a NAP-5 column (GE
Healthcare, Waukesha, WI, USA) equilibrated with PBS (10 mM,
pH 7.4, 140 mM NaCl).
Measurements of affinity in LigandTracer Grey
The binding of
125I-EGF to seeded cells were monitored in real-
time at room temperature using LigandTracer Grey, as described
preciously by Bjo ¨rke and Andersson [23]. Five increasing
concentrations of
125I-EGF in complete medium was added in
each affinity titration assay. The measurements were performed in
duplicates for each cell line and different concentration series were
used to fully cover the concentration span needed for a proper
affinity estimation (Table 1). Each concentration was incubated
long enough to approach steady state, from 1 hour for the highest
concentrations to 3.5 hours for the lowest.
Figure 3. The effect of gefitinib and starvation on the
125I-EGF-EGFR interaction on A431 cells. Binding curves from the
125I-EGF-A431
measurements, with three-four replicates for each treatment: (A) control, (B) starvation, (C) gefitinib and (D) gefitinib +starvation.
doi:10.1371/journal.pone.0016536.g003
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U343 cells were incubated with 4.5 nM
125I-EGF in room
temperature for 24 hours while detecting the
125I-EGF binding
level in LigandTracer Grey. In case of internalization, EGF would
be metabolized and free
125I would be excreted by the cells,
resulting in a decreasing signal over time.
Data analysis
The kinetic data from the affinity measurements were analyzed
in TraceDrawer (Ridgeview Instruments AB, Uppsala, Sweden)
and fitted to kinetic interaction models describing a monovalent
ligand binding to either one (1:1) target or two (1:2) independent
targets.
The estimated steady-state signals from both affinity measure-
ments were analyzed simultaneously in MATLAB 6.5 (The
Mathworks, Natick, MA, USA) and a 1:1 steady state interaction
model was fitted using non-linear regression to obtain the
equilibrium dissociation constant, KD.
In order to enhance visibility of the acquired binding curves, a
moving window Fourier transform noise reduction algorithm was
applied. Noise with a frequency higher than approximately
0.01 Hz was removed, resulting in noise-reduced curves where
the biologically relevant curvature was preserved.
Cell treatments
Four kinds of treatment of the cells were tested: (a) in normal
cell culture medium, as described above, (b) in cell culture medium
devoid of fetal calf serum, (c) in cell culture medium supplemented
with 1 mM gefitinib (Biaffin GmbH, Kassel, Germany) and (d) in
cell culture medium devoid of serum but with 1 mM gefitinib. The
cell culture medium of the starvation dishes (b) were exchanged
with serum free Ham’s F10 24 h prior to measurement. The
gefitinib dishes (c) were incubated with 1 mM gefitinib 48 h before
Figure 4. The effect of gefitinib and starvation on the
125I-EGF-EGFR interaction on four tumor cell lines.
125I-EGF binding to A431 (A),
U343 (B), SKOV3 (C) and SKBR3 (D), using four different treatments: control (red), starvation (blue), 1 mM gefitinib (green) and 1 mM gefitinib +
starvation (black). Data shows that the affinity of the EGF-EGFR interaction on A431 and SKOV3 is affected by gefitinib exposure and that the effect is
boosted in starvation medium. U343 cells are sensitive to starvation and possible to some extent to gefitinib (slower dissociation). SKBR3 cells seem
unaffected by all treatments.
doi:10.1371/journal.pone.0016536.g004
Table 1. Summary of concentrations tested.
Affinity titration Cell treatment assay
Cell line Concentration span Conc. 1 (nM) Conc. 2 (nM)
A431 0.3;1;3;9;28 nM 2.8 9
A431 3;9;36;72;138 nM
U343 0.1;0.3;0.9;2.8;9.4 nM 0.5 1.5
U343 0.1;0.4;1.6;6.6;26 nM
SKOV3 0.1;0.3;0.9;2.8 nM 0.7 2
SKOV3 0.05;0.15;0.5;1.5;4.6 nM
SKBR3 0.3;1;3;9;28 nM 0.2 0.8
SKBR3 0.1;0.3;1;3;9 nM
Concentrations of
125I-EGF tested on the four cell lines in the cell treatment
assay and the affinity titration assay.
doi:10.1371/journal.pone.0016536.t001
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24 h to ensure a continuous gefitinib exposure. Prior to retention
measurements, more gefitinib was added to ensure a fresh gefitinib
concentration of at least 1 mM. The gefitinib +starvation dishes (d)
were treated similar to (c), but with serum free medium +1 mM
gefitinib added 24 h prior to measurement.
Measurements of cell treatment effects in LigandTracer
Grey
Detections of treatment effects were performed at room
temperature using LigandTracer Grey. All measurements were
conducted in 3 ml cell culture medium and started with a short
baseline, followed by a two-step uptake study using increasing
concentrations of
125I-EGF (Table 1), followed by a retention
measurement over night in cell culture medium. The incubation
times were approximately 3.5+4 h for all cell lines. Each of the 16
cell-treatments was measured at least 2 times, often 3–4 times,
resulting in mainly triplicate and quadruplicate results.
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